http://www.avibio.com/ AVI BioPharma News and Press Releases Tue, 3 August 2009 08:00:00 PDT http://www.avibio.com/pr/pr0071.phpBOTHELL, WA - February 5, 2010Fri, 5 February 2010 05:00:00 PSThttp://www.avibio.com/pr/pr0071.phphttp://www.avibio.com/pr/pr0070.phpBOTHELL, WA - February 4, 2010 - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that the results and scientific findings of Good Laboratory Practice (GLP)-compliant safety pharmacology and genotoxicity evaluations of AVI-4658, a drug candidate being developed by AVI for the treatment of Duchenne Muscular Dystrophy (DMD), were published online in the International Journal of Toxicology.Thu, 4 February 2010 05:00:00 PSThttp://www.avibio.com/pr/pr0070.phphttp://www.avibio.com/pr/pr0069.phpBOTHELL, WA - January 15, 2010Fri, 15 January 2010 05:00:00 PSThttp://www.avibio.com/pr/pr0069.phphttp://www.avibio.com/pr/pr0068.phpBOTHELL, WA - December 22, 2009Tue, 22 December 2009 04:00:00 PSThttp://www.avibio.com/pr/pr0068.phphttp://www.avibio.com/pr/pr0067.phpBOTHELL, WA - November 19, 2009Thu, 19 November 2009 05:00:00 PSThttp://www.avibio.com/pr/pr0067.phphttp://www.avibio.com/pr/pr0066.phpBOTHELL, WA - November 18, 2009Wed, 18 November 2009 05:00:00 PSThttp://www.avibio.com/pr/pr0066.phphttp://www.avibio.com/pr/pr0065.phpBOTHELL, WA - November 9, 2009Mon, 9 November 2009 05:00:00 PSThttp://www.avibio.com/pr/pr0065.phphttp://www.avibio.com/pr/pr0064.phpBOTHELL, WA - November 2, 2009 - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, will hold a conference call to report third quarter 2009 financial results on Monday, Nov. 9, 2009, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time).Mon, 2 November 2009 08:00:00 PSThttp://www.avibio.com/pr/pr0064.phphttp://www.avibio.com/pr/pr0063.phpBOTHELL, WA - October 26, 2009Mon, 26 October 2009 05:00:00 PDThttp://www.avibio.com/pr/pr0063.phphttp://www.avibio.com/pr/pr0062.phpBOTHELL, WA - October 22, 2009Thu, 22 October 2009 05:00:00 PDThttp://www.avibio.com/pr/pr0062.phphttp://www.avibio.com/pr/pr0061.phpOXFORD, UNITED KINGDON AND BOTHELL, WA - October 20, 2009 - An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan. These findings were published online today in the journal Molecular Therapy and support the promise of this therapeutic approach for the treatment of Duchenne muscular dystrophy (DMD). These results were published by researchers at University of Oxford, AVI BioPharma, Inc. (Nasdaq: AVII) and the University of Western Australia, Perth.Tue, 20 October 2009 07:00:00 PDThttp://www.avibio.com/pr/pr0061.phphttp://www.avibio.com/pr/pr0060.phpBOTHELL, WA - October 19, 2009Mon, 19 October 2009 05:04:00 PDThttp://www.avibio.com/pr/pr0060.php